Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patisiran in hATTR Amyloidosis Post-Liver Transplant
NCT03862807Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Oct 2020
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of patisiran in hereditary transthyretin amyloidosis (hATTR), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Average of Month 6 and Month 12 Percentage Reduction From Baseline in Serum Transthyretin (TTR). Started Mar 2019; status: completed.
02
Drugs
patisiran
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on NCT03862807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862807.